Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Drug Overdose - Overview
Drug Overdose - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Drug Overdose - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Overdose - Companies Involved in Therapeutics Development
Adamis Pharmaceuticals Corp
Amphastar Pharmaceuticals Inc
Crossject SA
Emergent BioSolutions Inc
Fab’entech SA
Icure Pharmaceutical Inc
Insys Therapeutics Inc
InterveXion Therapeutics LLC
Klaria Pharma Holding AB
Mucodel Pharma LLC
Opiant Pharmaceuticals Inc
Orexo AB
PledPharma AB
ResQ Pharma Inc
Vallon Pharmaceuticals Inc
Worphmed Srl
Drug Overdose - Drug Profiles
Antibody for Drug Overdose, Opioid Addiction and Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dribant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IXTf-250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lmefene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lmefene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loxone hydrochloride 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loxone. - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPNT-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
physostigmine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Drug Overdose and Drug Toxicity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Alzheimer’s Disease and Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Substance Abuse and Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug Overdose - Dormant Projects
Drug Overdose - Discontinued Products
Drug Overdose - Product Development Milestones
Featured News & Press Releases
Aug 17, 2020: Emergent BioSolutions announces FDA approval of RCAN (loxone HCl) sal spray shelf life extension to 36 months
Jul 01, 2020: Klaria Pharma initiates clinical program for loxone Algite Film to prevent opioid overdose
Jun 30, 2020: Positive results from human PK study assessing Orexo’s intrasal lmefene formulations for opioid overdose reversal
Jun 18, 2020: Adamis Pharmaceuticals announces publication of pharmacokinetic model suggesting that higher doses of loxone are needed for successful resuscitation due to fentanyl overdose
Jun 05, 2020: Opiant Pharmaceuticals statement on U.S. District Court decision
May 27, 2020: Adamis Pharmaceuticals announces publication of pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of loxone
May 18, 2020: Adamis Pharmaceuticals resubmits ZIMHI New Drug Application to FDA
Apr 23, 2020: Adamis Pharmaceuticals announces Publication demonstrating PET Scan results of higher dose loxone in Monkeys
Dec 19, 2019: Adamis Pharmaceuticals provides an update on ZIMHI
Dec 12, 2019: Opiant Pharmaceuticals announces contract extension of second tranche of approximately $2.4 million from Biomedical Advanced Research and Development Authority for development of OPNT003, sal lmefene, for the treatment of Opioid Overdose
Nov 26, 2019: FDA rejects Adamis’ NDA for high-dose loxone against opioid overdose
Nov 18, 2019: Adamis Pharmaceuticals announces publication of comparative pharmacokinetics of community use loxone formulations
Nov 04, 2019: Adamis Pharmaceuticals provides regulatory update for its higher dose loxone Pre-Filled Syringe
Oct 08, 2019: Adamis Pharmaceuticals announces presentation of ZIMHI data at IHV Scientific Meeting
Sep 26, 2019: Adamis Pharmaceuticals announces presentation pertaining to its high dose loxone product candidate at IHV Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Drug Overdose, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Drug Overdose, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Drug Overdose - Pipeline by Adamis Pharmaceuticals Corp, H2 2020
Drug Overdose - Pipeline by Amphastar Pharmaceuticals Inc, H2 2020
Drug Overdose - Pipeline by Crossject SA, H2 2020
Drug Overdose - Pipeline by Emergent BioSolutions Inc, H2 2020
Drug Overdose - Pipeline by Fab’entech SA, H2 2020
Drug Overdose - Pipeline by Icure Pharmaceutical Inc, H2 2020
Drug Overdose - Pipeline by Insys Therapeutics Inc, H2 2020
Drug Overdose - Pipeline by InterveXion Therapeutics LLC, H2 2020
Drug Overdose - Pipeline by Klaria Pharma Holding AB, H2 2020
Drug Overdose - Pipeline by Mucodel Pharma LLC, H2 2020
Drug Overdose - Pipeline by Opiant Pharmaceuticals Inc, H2 2020
Drug Overdose - Pipeline by Orexo AB, H2 2020
Drug Overdose - Pipeline by PledPharma AB, H2 2020
Drug Overdose - Pipeline by ResQ Pharma Inc, H2 2020
Drug Overdose - Pipeline by Vallon Pharmaceuticals Inc, H2 2020
Drug Overdose - Pipeline by Worphmed Srl, H2 2020
Drug Overdose - Dormant Projects, H2 2020
Drug Overdose - Discontinued Products, H2 2020